Arcturus Therapeutics In... (ARCT)
Arcturus Therapeutics Statistics
Share Statistics
Arcturus Therapeutics has 27.12M shares outstanding. The number of shares has increased by 0.7% in one year.
Shares Outstanding | 27.12M |
Shares Change (YoY) | 0.7% |
Shares Change (QoQ) | 0.12% |
Owned by Institutions (%) | 98.46% |
Shares Floating | 24.37M |
Failed to Deliver (FTD) Shares | 5.71K |
FTD / Avg. Volume | 1.39% |
Short Selling Information
The latest short interest is 5.04M, so 18.62% of the outstanding shares have been sold short.
Short Interest | 5.04M |
Short % of Shares Out | 18.62% |
Short % of Float | 20.52% |
Short Ratio (days to cover) | 11.98 |
Valuation Ratios
The PE ratio is -5.66 and the forward PE ratio is -11.04. Arcturus Therapeutics's PEG ratio is -0.03.
PE Ratio | -5.66 |
Forward PE | -11.04 |
PS Ratio | 3.01 |
Forward PS | 0.3 |
PB Ratio | 1.9 |
P/FCF Ratio | -7.59 |
PEG Ratio | -0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Arcturus Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.67, with a Debt / Equity ratio of 0.1.
Current Ratio | 4.67 |
Quick Ratio | 4.67 |
Debt / Equity | 0.1 |
Debt / EBITDA | -0.32 |
Debt / FCF | -0.41 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $875.34K |
Profits Per Employee | $-465.18K |
Employee Count | 174 |
Asset Turnover | 0.44 |
Inventory Turnover | n/a |
Taxes
Income Tax | -4K |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -70.73% in the last 52 weeks. The beta is 2.96, so Arcturus Therapeutics's price volatility has been higher than the market average.
Beta | 2.96 |
52-Week Price Change | -70.73% |
50-Day Moving Average | 15.31 |
200-Day Moving Average | 19.17 |
Relative Strength Index (RSI) | 22.4 |
Average Volume (20 Days) | 412.07K |
Income Statement
In the last 12 months, Arcturus Therapeutics had revenue of 152.31M and earned -80.94M in profits. Earnings per share was -3.
Revenue | 152.31M |
Gross Profit | 152.31M |
Operating Income | -95.67M |
Net Income | -80.94M |
EBITDA | -77.4M |
EBIT | -80.94M |
Earnings Per Share (EPS) | -3 |
Balance Sheet
The company has 237.03M in cash and 25M in debt, giving a net cash position of 212.03M.
Cash & Cash Equivalents | 237.03M |
Total Debt | 25M |
Net Cash | 212.03M |
Retained Earnings | -448.81M |
Total Assets | 344.07M |
Working Capital | 240.49M |
Cash Flow
In the last 12 months, operating cash flow was -59.75M and capital expenditures -648K, giving a free cash flow of -60.4M.
Operating Cash Flow | -59.75M |
Capital Expenditures | -648K |
Free Cash Flow | -60.4M |
FCF Per Share | -2.24 |
Margins
Gross margin is 100%, with operating and profit margins of -62.81% and -53.14%.
Gross Margin | 100% |
Operating Margin | -62.81% |
Pretax Margin | -53.14% |
Profit Margin | -53.14% |
EBITDA Margin | -50.82% |
EBIT Margin | -62.81% |
FCF Margin | -39.65% |
Dividends & Yields
ARCT does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for ARCT is $60, which is 536.3% higher than the current price. The consensus rating is "Buy".
Price Target | $60 |
Price Target Difference | 536.3% |
Analyst Consensus | Buy |
Analyst Count | 6 |
Stock Splits
The last stock split was on Nov 16, 2017. It was a backward split with a ratio of 1:7.
Last Split Date | Nov 16, 2017 |
Split Type | backward |
Split Ratio | 1:7 |
Scores
Altman Z-Score | 0.2 |
Piotroski F-Score | 3 |